1190391-62-8Relevant articles and documents
Investigation of piperazine benzamides as human β3 adrenergic receptor agonists for the treatment of overactive bladder
Harper, Bart H.,Wang, Liping,Zhu, Cheng,Kar, Nam F.,Li, Bing,Moyes, Christopher R.,Goble, Stephen D.,Costa, Melissa,Dingley, Karen,Di Salvo, Jerry,Ha, Sookhee N.,Hurley, Amanda,Li, Xiaofang,Miller, Randy R.,Nagabukuro, Hiroshi,Salituro, Gino M.,Smith, Sean,Struthers, Mary,Hale, Jeffrey J.,Edmondson, Scott D.,Berger, Richard
, p. 1094 - 1098 (2017/09/30)
The synthesis of a novel class of piperazine benzamide (reverse amides) targeting the human β3-adrenergic receptor for the treatment of overactive bladder (OAB) is described. The SAR studies directed towards maintaining well established β3 potency and selectivities while improving the overall pharmacokinetic profile in the reverse amide class will be evaluated. The results and consequences associated with functional activity at the norepinephrine transporter (NET) will also be discussed.
NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS
-
, (2011/11/13)
The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of b3-adrenoceptor.
HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
-
, (2009/10/17)
The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.